These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28784284)

  • 21. Immune protection induced on day 10 following administration of the 2009 A/H1N1 pandemic influenza vaccine.
    Sun Y; Bian C; Xu K; Hu W; Wang T; Cui J; Wu H; Ling Z; Ji Y; Lin G; Tian L; Zhou Y; Li B; Hu G; Yu N; An W; Pan R; Zhou P; Leng Q; Huang Z; Ma X; Sun B
    PLoS One; 2010 Dec; 5(12):e14270. PubMed ID: 21151563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune response to 2009 pandemic H1N1 influenza virus A monovalent vaccine in children with cancer.
    Yen TY; Jou ST; Yang YL; Chang HH; Lu MY; Lin DT; Lin KH; Huang LM; Chang LY
    Pediatr Blood Cancer; 2011 Dec; 57(7):1154-8. PubMed ID: 21425448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seasonal influenza vaccines induced high levels of neutralizing cross-reactive antibody responses against different genetic group influenza A(H1N1)pdm09 viruses.
    Haveri A; Ikonen N; Kantele A; Anttila VJ; Ruotsalainen E; Savolainen-Kopra C; Julkunen I
    Vaccine; 2019 May; 37(20):2731-2740. PubMed ID: 30954308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relation of activation-induced deaminase (AID) expression with antibody response to A(H1N1)pdm09 vaccination in HIV-1 infected patients.
    Cagigi A; Pensieroso S; Ruffin N; Sammicheli S; Thorstensson R; Pan-Hammarström Q; Hejdeman B; Nilsson A; Chiodi F
    Vaccine; 2013 Apr; 31(18):2231-7. PubMed ID: 23499520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of a monovalent pandemic influenza A H1N1 virus vaccine with or without prior seasonal influenza vaccine administration.
    Igari H; Watanabe A; Segawa S; Suzuki A; Watanabe M; Sakurai T; Watanabe M; Tatsumi K; Nakayama M; Suzuki K; Sato T
    Clin Vaccine Immunol; 2012 Oct; 19(10):1690-2. PubMed ID: 22855394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine.
    Zhou Y; Ng DM; Seto WH; Ip DK; Kwok HK; Ma ES; Ng S; Lau LL; Peiris JS; Cowling BJ
    PLoS One; 2011; 6(11):e27169. PubMed ID: 22102878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and sustainability of the immune response in Brazilian HIV-1-infected individuals vaccinated with inactivated triple influenza vaccine.
    Souza TM; Santini-Oliveira M; Martorelli A; Luz PM; Vasconcellos MT; Giacoia-Gripp CB; Morgado M; Nunes EP; Lemos AS; Ferreira AC; Moreira RI; Veloso VG; Siqueira M; Grinsztejn B; Camacho LA
    J Med Virol; 2016 Mar; 88(3):426-36. PubMed ID: 26267817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low response to a monovalent inactivated unadjuvanted influenza A (H1N1) pdm09 vaccine in pediatricians of a general hospital in Japan.
    Hata A; Mano C; Nakamura Y; Nishida H; Kumakura A; Mizumoto H; Yoshioka T; Yoshida Y; Shiota M; Hata D; Takahashi K
    Hum Vaccin Immunother; 2012 May; 8(5):587-91. PubMed ID: 22634447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.
    Maruszak H; Jeganathan S; Smith DE; Robertson P; Barnes T; Furner V
    HIV Med; 2012 Jul; 13(6):352-7. PubMed ID: 22296264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term immunogenicity of the pandemic influenza A/H1N1 2009 vaccine among health care workers: influence of prior seasonal influenza vaccination.
    Song JY; Cheong HJ; Seo YB; Kim IS; Noh JY; Choi WS; Lee J; Jeong HW; Kee SY; Kim WJ
    Clin Vaccine Immunol; 2013 Apr; 20(4):513-6. PubMed ID: 23365206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
    Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pandemic influenza A(H1N1)pdm09 improves vaccination routine in subsequent years: a cohort study from 2009 to 2011.
    Tacken MA; Jansen B; Mulder J; Visscher S; Heijnen ML; Campbell SM; Braspenning JC
    Vaccine; 2013 Jan; 31(6):900-5. PubMed ID: 23246546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic?
    Mahmud SM; Bozat-Emre S; Hammond G; Elliott L; Van Caeseele P
    PLoS One; 2015; 10(11):e0142754. PubMed ID: 26600435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.
    Zhan Y; Yang Z; Li L; Ye D; Wu H; Fu R; Zhao S; Wang Y; Zhou R; Chen R
    Jpn J Infect Dis; 2011; 64(3):190-4. PubMed ID: 21617301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.
    Nolan T; McVernon J; Skeljo M; Richmond P; Wadia U; Lambert S; Nissen M; Marshall H; Booy R; Heron L; Hartel G; Lai M; Basser R; Gittleson C; Greenberg M
    JAMA; 2010 Jan; 303(1):37-46. PubMed ID: 20026597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.